How effective is selinesol? Can clinical recruitment be found?

Selinexor in combination with dexamethasone has shown activity in patients with heavily pretreated multiple myeloma(MM). In a phase 1b/2 study, the combination of oral selinesol with bortezomib (a proteasome inhibitor) and dexamethasone induced a high response rate and a low rate of peripheral neuropathy, the major dose-limiting toxicity of bortezomib. This trial was designed to evaluate the clinical benefit of weekly selinesol, bortezomib, and dexamethasone versus standard bortezomib and dexamethasone in patients with previously treated multiple myeloma.

Methods:This Phase 3 randomized open trial was conducted at 123 sites in 21 countries. Multiple myeloma patients who are 18 years old or older and have previously received 1-3 treatments(Patients including proteasome inhibitors) were randomly assigned(1:1)to receive selinesol(100 mg, once weekly), bortezomib(1-3mg/m2once weekly)and dexamethasone(20 mg twice a week) or bortezomib(1-3 mg/m2 twice a week for the first 24 weeks and then once a week after )and dexamethasone (before 24four times a week, then twice a week 20 mg). Randomization was performed using the reciprocal response technique and stratified by prior proteasome inhibitor therapy, treatment regimen, and multiple myeloma stage. The primary endpoint was progression-free survival in the intention-to-treat population. Patients who received at least one dose of study treatment were included in the safety population.

Survey results:After screening qualified onesOf the 457 patients, 402 were randomly assigned-195(4 9%)were assigned to selinesol, bortezomib, and dexamethasone, and 207names(51%)were assigned to bortezomib and dexamethasone. The first dose of study drug in the pine group-was given in2017year6monthIt will be given between day 2019year2month5day. The median follow-up time in the selinesol, bortezomib, and dexamethasone group was 13 months ± 2 months [IQR 6±2-19±8], the median follow-up time in the bortezomib and dexamethasone groups was 16±5months[9±4-19±8]. Median progression-free survival with selinesol, bortezomib, and dexamethasone was 13 93 months (95% CI 11 73-Not evaluable), median progression-free survival with bortezomib and dexamethasone is 9 46 months(8 11-10 78)(Hazard ratio 0 70 [95% CI 0 53-0 93], p=0 0075). The most common grade 3-4 adverse event was thrombocytopenia(Selinisole, bortezomib, and dexamethasone groups195 77 of [39%] vs. bortezomib and dexamethasone 20 35 out of 4patients[17%]), fatigue(26cases[13%]right2cases[1%]), anemiaand the lungs inflammation(22cases[11%]Yes22cases[11%]). Patients on selinexole, bortezomib, and dexamethasone(41[21%]compared to patients on bortezomib and dexamethasone(70[34%]) = 0.0013). There were 47 (24%) deaths in the selinesol, bortezomib and dexamethasone group and 62 (30%) deaths in the bortezomib and dexamethasone group.

Conclusion:A weekly regimen of selinisole, bortezomib, and dexamethasone is a novel, effective, and convenient treatment option for patients with multiple myeloma who have received 1-3 prior lines of therapy.

Selinesol was officially launched in China on July 24, 2022, so there is currently no clinical recruitment. The cost of each box of generic drugs is about three to four thousand yuan. For details, please consult overseas pharmaceutical institutions. If you want to get more high-quality information, you can contact YaoDe. YaoDe will do its best to learn more about high-quality overseas drugs for you.